Page 502 - O_Desenvolvimento_do_Autismo
P. 502

ERNST, M.; ZAMETKIN, A.; MATOCHIK, J.; PASCUALVACA, D. e
                COHEN, R. “Low medial prefrontal dopaminergic activity in autistic
                children”. Lancet 350(9078), 1997, p. 638.






                ESCALONA, A.; FIELD, T.; SINGER-STRUNCK, R.; CULLEN, C. e

                HARTSHORN, K. “Improvements in the behavior of children with autism
                following massage therapy”. Journal of Autism and Developmental
                Disorders 31, 2001, pp. 90-95.






                FATEMI, S.; HALT, A.; STARY, A.; KANODIA, J.; SCHULZ, R. e
                REALMUTO, G. “Glutamic acid decarboxylase 65 and 67 kDa proteins are
                reduced in autistic parietal and cerebellar cortices”. Biological Psychiatry
                52, 2002, pp. 805-810.






                FDA (US Food and Drug Administration). “FDA talk paper: FDA issues

                final ruling on OTC products containing colloidal silver”. Disponível em
                <www.fda.gov/bbs/topics/ANSWERS/ANS00971.html>, 1999.






                FEINBERG, E. e VACCA, J. “The drama and trauma of creating policies on
                autism: critical issues to consider in the new millennium”. Focus on Autism
                and Other Developmental Disabilities 15, 2000, pp. 130-137.






                FERNELL, E.; WATANABE, Y.; ADOLFSSON, I.; TANI, Y.;
                BERGSTROM, M.; HARTVIG, P.; LILJA, A.; VON KNORRING, A. L.;

                GILLBERG, C. e LANGSTROM, B. “Possible effects of tetrahydrobiopterin
                treatment in six children with autism - clinical and positron emission
                tomography data: a pilot study”. Developmental Medicine and Child
                Neurology 39, 1997, pp. 313-318.
   497   498   499   500   501   502   503   504   505   506   507